APM Key Statistics, Chart & Performance
The current stock price of APM is 1.12 USD. In the past month the price decreased by -14.5%. In the past year, price increased by 3.7%.
APM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.21 | 404.36B | ||
| AMGN | AMGEN INC | 15.16 | 178.50B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.45 | 116.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 781.76 | 52.67B | ||
| INSM | INSMED INC | N/A | 37.70B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 10.44 | 25.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.34 | 21.98B | ||
| INCY | INCYTE CORP | 15.72 | 19.81B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About APM
Company Profile
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Company Info
APTORUM GROUP LTD-CLASS A
17 Hanover Square
London W1S 1BN GB
CEO: Ian Huen
Employees: 1
Phone: 85239537700
APTORUM GROUP LTD-CLASS A / APM FAQ
What does APTORUM GROUP LTD-CLASS A do?
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
What is the current price of APM stock?
The current stock price of APM is 1.12 USD. The price decreased by -4.27% in the last trading session.
Does APTORUM GROUP LTD-CLASS A pay dividends?
APM does not pay a dividend.
What is the ChartMill technical and fundamental rating of APM stock?
APM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does APTORUM GROUP LTD-CLASS A belong to?
APTORUM GROUP LTD-CLASS A (APM) operates in the Health Care sector and the Biotechnology industry.
What is APTORUM GROUP LTD-CLASS A worth?
APTORUM GROUP LTD-CLASS A (APM) has a market capitalization of 9.12M USD. This makes APM a Nano Cap stock.
What is the Short Interest ratio of APTORUM GROUP LTD-CLASS A (APM) stock?
The outstanding short interest for APTORUM GROUP LTD-CLASS A (APM) is 0.49% of its float.
APM Technical Analysis
APM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APM. APM has a bad profitability rating. Also its financial health evaluation is rather negative.
APM Financial Highlights
Over the last trailing twelve months APM reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.46% | ||
| ROE | -20.19% | ||
| Debt/Equity | 0 |
APM Forecast & Estimates
For the next year, analysts expect an EPS growth of 8528.57% and a revenue growth -78.44% for APM